Michael S. Ominsky, PhD

Ascendis Pharma, Inc.
Palo Alto, California, United States

Disclosure information not submitted.

Presentation(s):

• ORF16-07 - Palopegteriparatide Treatment in Adults with Hypoparathyroidism: Final Results of the Phase 3 PaTHway Trial

  Saturday, June 13, 2026
  2:45 PM - 3:00 PM CT

• ORF47-06 - Navepegritide Combined with Lonapegsomatropin for the Treatment of Achondroplasia: An Open-Label Phase 2 Trial

  Monday, June 15, 2026
  2:30 PM - 2:45 PM CT